Literature DB >> 22959319

Clinical outcome score predicts the need for neurodevelopmental intervention after infant heart surgery.

Andrew S Mackie1, Gwen Y Alton, Irina A Dinu, Ari R Joffe, Stephen J Roth, Jane W Newburger, Charlene M T Robertson.   

Abstract

OBJECTIVE: Our goal was to determine if a clinical outcome score derived from early postoperative events is associated with 18- to 24-month Psychomotor Developmental Index (PDI) score among infants undergoing cardiopulmonary bypass surgery.
METHODS: We included infants aged ≤6 weeks who underwent surgery during 2002-2006, all of whom were referred for neurodevelopmental evaluation at age 18 to 24 months. We excluded children with chromosomal abnormalities, hearing loss, cerebral palsy, or a Bayley III assessment. The prespecified clinical outcome score had a range of 0 to 7. Lower scores indicated a more rapid postoperative recovery. Patients requiring extracorporeal membrane oxygenation were assigned a score of 7.
RESULTS: Ninety-nine subjects were included. Surgical procedures were arterial switch (n = 36), Norwood (n = 26), repair of total anomalous pulmonary venous connection (n = 16), and other (n = 21). Four subjects had postoperative extracorporeal membrane oxygenation. Clinical outcome scores were highest in the Norwood group (mean 4.1 ± 1.4) compared with the arterial switch group (1.9 ± 1.6) (P < .001), total anomalous pulmonary venous connection group (1.6 ± 2.0) (P < .001), and other group (3.3 ± 1.6, P = not significant). A mean decrease in PDI of 10.9 points (95% confidence interval, 4.9-16.9; P = .0005) was observed among children who had a clinical outcome score ≥3, compared with those with a clinical outcome score <3. Time until lactate ≤2.0 mmol/L increased with increasing clinical outcome score (P = .0003), as did highest 24-hour inotrope score (P < .0001).
CONCLUSIONS: Clinical outcome scores of ≥3 were associated with a significantly lower PDI at age 18 to 24 months. This score may be valuable as an end point when evaluating novel potential therapies for this high-risk population.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959319     DOI: 10.1016/j.jtcvs.2012.04.029

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

Review 1.  Current status of brain protection during surgery for congenital cardiac defect.

Authors:  Takahiko Sakamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-11-30

2.  Perioperative Management of a Child with Hypoplastic Left Heart Syndrome of the Jehovah's Witness Faith Presenting for Hybrid Comprehensive Stage II Procedure.

Authors:  Sathappan Karuppiah; Christopher Mckee; Ashley Hodge; Mark Galantowicz; Joseph Tobias; Aymen Naguib
Journal:  J Extra Corpor Technol       Date:  2016-09

3.  Early childhood language outcomes after arterial switch operation: a prospective cohort study.

Authors:  Matt S Hicks; Reginald S Sauve; Charlene M T Robertson; Ari R Joffe; Gwen Alton; Dianne Creighton; David B Ross; Ivan M Rebeyka
Journal:  Springerplus       Date:  2016-09-29

4.  Intellectual Functioning in Children with Congenital Heart Defects Treated with Surgery or by Catheter Interventions.

Authors:  Carmen Ryberg; Jan Sunnegårdh; Maria Thorson; Malin Broberg
Journal:  Front Pediatr       Date:  2016-11-17       Impact factor: 3.418

5.  A referral pathway for potentially abnormal neurodevelopment in children with heart disease in the United Kingdom: a Delphi consensus.

Authors:  Aparna Hoskote; Jo Wray; Victoria Banks; Katherine Brown; Monica Lakhanpaul
Journal:  BMJ Paediatr Open       Date:  2020-04-21

Review 6.  Developmental outcomes after early surgery for complex congenital heart disease: a systematic review and meta-analysis.

Authors:  Darlene Huisenga; Sacha La Bastide-Van Gemert; Andrew Van Bergen; Jane Sweeney; Mijna Hadders-Algra
Journal:  Dev Med Child Neurol       Date:  2020-03-09       Impact factor: 5.449

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.